EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The breakthrough and the future: CD20 chimeric antigen receptor T‐cell therapy for hematologic malignancies

Elaine Tan Su Yin, Yong Xian Hu, He Huang

ImmunoMedicine · 2022

DOI: 10.1002/imed.1039 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ImmunoMedicine, 2022. Verfasst von Elaine Tan Su Yin und 2 weiteren Autor:innen. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptors (CAR) T‐cell therapy is one of the most effective treatments in curing hematologic malignancies. Besides the four CD19 CAR T‐cells therapy recently approved by the US Food and Drug Administration (FDA), CD20 CAR T‐cell therapy is now another effective treatment option for relapsed or refractory non‐Hodgkin lymphoma (NHL). CD20 CAR T‐cell infusion has achieved remarkable clinical outcomes in patients with B‐cell malignancies. This review will cover the current situations, advantages, limitations, prospects, and application of CD20 CAR T‐cell therapy.

Zitieren

APA

Yin, E. T. S., Hu, Y. X., & Huang, H. (2022). The breakthrough and the future: CD20 chimeric antigen receptor T‐cell therapy for hematologic malignancies. ImmunoMedicine. https://doi.org/10.1002/imed.1039

Vancouver

Yin ETS, Hu YX, Huang H. The breakthrough and the future: CD20 chimeric antigen receptor T‐cell therapy for hematologic malignancies. ImmunoMedicine. 2022. doi:10.1002/imed.1039

BibTeX
@article{Yin2022,
  author = {Yin, Elaine Tan Su and Hu, Yong Xian and Huang, He},
  title = {The breakthrough and the future: CD20 chimeric antigen receptor T‐cell therapy for hematologic malignancies},
  journal = {ImmunoMedicine},
  year = {2022},
  doi = {10.1002/imed.1039}
}
Kostenlos starten →